Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

Do autologous blood re-infusion systems reduce the requirement for transfusion in patients undergoing total knee replacement? Is it a cost effective solution?

British Orthopaedic Association/Irish Orthopaedic Association Annual Congress (BOA/IOA)



Abstract

Aim

The aim of this study was to determine the effects of using the Bellovac autologous blood salvage system on blood transfusion requirements, adverse event rate, post-operative length of stay (POLOS) and mobilisation in patients who have undergone a total knee replacement.

Methods

This is a retrospective cohort study of 471 patients who underwent a total knee replacement (TKR) at our institution between January 2008 and August 2009. All patients received an autologous blood salvage drain in theatre. Their medical records were reviewed and a database created to assess the efficacy of the blood salvage system.

Results

Overall 70% of the patients were re-transfused (77% of males, 65% of females). In the remainder there was too little blood in the drain by the time the re-transfusion window had ended. Re-transfused patients were comparable to those not re-transfused in terms of age, BMI, comorbidity, pre-op mobility, anaesthetic type and pre-operative haemoglobin concentration. Re-transfused patients had lower allogeneic transfusion requirements (6.5 vs 12.9%, p=0.022). This was not a result of the gender discrepancy. Number needed to treat with a re-infusion drain was 8.9 (95%CI 5.8–19.3) to prevent one unit of allogeneic blood being transfused. Re-transfused patients also had a lower post-operative adverse event rate (18 vs 24% p=0.18) but this was not statistically significant. POLOS and post-operative mobilisation were not affected, even after the elimination of patients with adverse events. Cost analysis showed that autologous re-infusion drains (£50 each) were not cost-effective in preventing allogeneic blood transfusion (vein-to-vein cost £135). One adverse event attributable to the re-infusion system occurred: a drain tip had to be removed operatively after becoming bent.

Conclusion

Autologous re-infusion systems are effective but not cost-effective in reducing blood transfusion requirement after TKR. Autologous re-infusion may be associated with a reduced adverse event rate post-operatively.